Rudick, R A <br/><br/>
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)  [electronic resource] 

 -  Neurology  May 1998 
 - 1266-72 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase III; Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0028-3878 
<br/><br/><label>Standard No.: </label>10.1212/wnl.50.5.1266  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antigen-Antibody Reactions<br/>Double-Blind Method<br/>Humans<br/>Interferon beta-1a<br/>Interferon-beta--immunology<br/>Middle Aged<br/>Multiple Sclerosis--drug therapy